<DOC>
	<DOCNO>NCT00601913</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment erlotinib . PURPOSE : This clinical trial study well erlotinib work give surgery treat patient head neck cancer remove surgery .</brief_summary>
	<brief_title>Erlotinib Surgery Treating Patients With Head Neck Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - Identify tissue biomarkers ( primarily level phosphorylation individual C-terminal EGFR tyrosine site , measure nano-LC-MS/MS marker main downstream pathway activation P-AKT P-ERK , measure nano-LC-MS/MS clinically standardized IHC ) best associate response neoadjuvant erlotinib hydrochloride treatment patient resectable squamous cell carcinoma head neck ( HNSCC ) . - Determine best correlation level change different individual biomarkers ( e.g. , level C-terminal EGFR phosphorylation recruit adaptor marker downstream pathway activation ) order evaluate mechanism EGFR pathway activation HNSCC mechanisms EGFR pathway inhibition erlotinib hydrochloride HNSCC tissue . - Evaluate post-erlotinib hydrochloride up-regulation different receptor molecule HER2 3 , PDGFR , IGFR , mTOR , src , aurora kinase , already specific inhibitor available clinical study . Secondary - Evaluate efficacy overall response , safety , tolerability erlotinib hydrochloride surgery patient . - Evaluate role FDG-PET scan predictor response erlotinib hydrochloride . - Evaluate role PET/CT measure response short-term treatment erlotinib hydrochloride . - Evaluate incidence risk factor relapse surgical pathology specimen . OUTLINE : Patients group accord smoking status ( non-actively smoke [ smoking , smoke average &lt; 10 cigarette daily , smoke &lt; 1 year prior enrollment ] v actively smoke [ smoking average ≥ 10 cigarette daily smoke ≥ 1 year ] ) . - Non-actively smoking patient : Patients receive oral erlotinib hydrochloride 150 mg daily least 14 day . At day 15 patient undergo surgical resection tumor . - Actively smoke patient : Patients receive oral erlotinib hydrochloride 300 mg daily least 14 day . At day 15 patient undergo surgical resection tumor . Patients undergo biopsy baseline completion study treatment . Tissue sample analyze nano-liquid chromatography mass spectrometry ( nano-LC-MS/MS ) marker activation inhibition different EGFR downstream pathway : PKC , c-Cbl , P-Erk , P- Akt , P-RAF , src , STAT3 5 , cyclin D1 , D3 , p21 p27 , c-fos , E-cadherin , vimentin , correlative up-regulated receptor : Her 2 , Her 3 , Cox-2 , IGF , VEGF , PDGFR , kinases src aurora kinases A B . The result confirm western blot , protein array , immunohistochemistry . After completion study treatment , patient follow 1 month .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm squamous cell carcinoma ( SCC ) oral cavity , oropharynx , hypopharynx , larynx SCC base tongue , pharynx , larynx , hypopharynx eligible provide additional biopsy tissue already save Tumor Tissue Core Laboratory research purpose SCC oral cavity tonsil eligible already agree additional biopsy tumor adjacent normal tissue available molecular study Candidate surgical treatment establish date surgery ≥ 15 day window opportunity Measurable disease CT scan MRI No nasopharyngeal carcinoma PATIENT CHARACTERISTICS : Inclusion criterion : ECOG performance status 02 ANC &gt; 1,500/µL Platelet count &gt; 100,000/µL Total bilirubin &lt; 1.5 mg/dL AST/ALT &lt; 2 time upper limit normal Creatinine &lt; 1.5 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Exclusion criterion : Uncontrolled intercurrent illness include , limited , follow : Ongoing active infection psychiatric illness/social situation would limit compliance study requirement Significant history uncontrolled cardiac disease ( i.e. , uncontrolled hypertension , unstable angina , myocardial infarction within past 3 month ) Uncontrolled congestive heart failure Cardiomyopathy decrease ejection fraction History interstitial lung disease ( e.g. , pneumonitis pulmonary fibrosis ) evidence interstitial lung disease chest CT scan Clinically significant ophthalmologic abnormality HIV positivity PRIOR CONCURRENT THERAPY : More 1 year since prior chemotherapy , biologic therapy , hormonal therapy No prior radiotherapy chemotherapy tumor No prior EGFR inhibitor No concurrent grapefruit grapefruit juice No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage I squamous cell carcinoma oropharynx</keyword>
	<keyword>stage II squamous cell carcinoma oropharynx</keyword>
	<keyword>stage I squamous cell carcinoma larynx</keyword>
	<keyword>stage II squamous cell carcinoma larynx</keyword>
	<keyword>stage I squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage II squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage I squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage II squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage I verrucous carcinoma larynx</keyword>
	<keyword>stage I verrucous carcinoma oral cavity</keyword>
	<keyword>stage II verrucous carcinoma oral cavity</keyword>
</DOC>